Patient Resources / Glioblastoma

When glioblastoma comes back.

Glioblastoma, or GBM, is the most common malignant primary brain tumor in adults.1 Even with the best care available today, it almost always returns, and that return, recurrent glioblastoma, is what Cerenome treats.

1. Price M, Ballard C, Benedetti J, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017–2021. Neuro-Oncology. 2024;26(Suppl 6):vi1–vi85. doi:10.1093/neuonc/noae145

A tumor that resists treatment.

Glioblastoma is a fast-growing tumor that begins in the brain’s own cells. It doesn’t form a neat lump that can be lifted out; it weaves into the surrounding healthy brain, which makes it very hard to remove or treat completely. Because some tumor cells are almost always left behind, glioblastoma recurs in the large majority of people, usually within months of first treatment. Recurrent glioblastoma is where the need for new options is greatest.

1. Aman R, Desbassarie F, Lubis AR, Ardiansyah IR. Prognostic factors and survival of recurrent glioblastoma: a systematic review. Folia Med (Plovdiv). 2025;67(3). doi:10.3897/folmed.67.e142227

More than 90% of glioblastomas recur, typically within 6 to 9 months of first treatment.1

A circle of dots, more than nine in ten of them coral.

Treating Recurrent GBM

Why recurrent GBM is so hard to treat.

At recurrence, glioblastoma is often harder to treat than at first diagnosis, for reasons specific to how it’s already been managed.

It’s already been treated.

Recurrences usually appear in the same area that received full-dose radiation the first time, which limits how much more can safely be given there.

More radiation isn’t the answer.

Prior radiation can limit retreatment options. Because recurrent tumors often arise in areas that have already received radiation, additional external-beam radiation must be carefully balanced against the tolerance of surrounding healthy brain tissue.

There’s no standard next step.

Unlike newly diagnosed glioblastoma, recurrent glioblastoma has no single standard of care, and clinical trials are among the options guidelines recommend.

How Cerenome is working on it.

Two of glioblastoma’s hardest problems are that it sits behind the blood-brain barrier, out of reach of many treatments, and that it can’t safely be given enough radiation from outside the head. Cerenome’s investigational radiotherapeutic, REYOBIQ™, is designed to get around both.

It’s placed directly into the tumor through a method called convection-enhanced delivery (CED), past the barrier, and its nanoliposome design is built to hold a concentrated dose of radiation right where it’s placed, while limiting what reaches the healthy brain nearby. REYOBIQ™ is being studied in a Phase 2 clinical trial called ReSPECT-GBM.

These are investigational uses. The treatment is still being studied, and its safety and effectiveness have not been established. Your care team is the best guide to whether a clinical trial may be right for you.

Support & Resources

Where to learn more.

Signs and symptoms

Glioblastoma can cause headaches, seizures, nausea, changes in thinking, memory, or personality, and weakness or difficulty with speech or vision, depending on where the tumor is. Any new or worsening symptom is worth raising with your care team.

How glioblastoma is diagnosed

Diagnosis usually begins with an MRI, and is confirmed by examining tissue from surgery or a biopsy.

How it’s treated today

Standard first treatment is usually surgery to remove as much of the tumor as possible, followed by radiation and chemotherapy (temozolomide). At recurrence, there is no single standard of care; options may include another surgery, more radiation, other medicines, or a clinical trial.

Questions to ask your care team
  • Could a clinical trial be an option for me?
  • What would taking part involve, and what are the possible risks and benefits?
  • How would treatment be given, and what should I expect?
Where to find support